April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
The Impact of Intraocular Pressure Reduction on Retinal Ganglion Cell Function Measured Using Pattern Electroretinogram in Eyes Receiving Latanoprost 0.005% versus Placebo
Author Affiliations & Notes
  • M. Sehi
    Ophthalmology, Bascom Palmer Eye Institute, University of Miami, Palm Beach Gardens, Florida
  • D. S. Grewal
    Ophthalmology, Bascom Palmer Eye Institute, University of Miami, Palm Beach Gardens, Florida
  • D. S. Greenfield
    Ophthalmology, Bascom Palmer Eye Institute, University of Miami, Palm Beach Gardens, Florida
  • Footnotes
    Commercial Relationships  M. Sehi, None; D.S. Grewal, None; D.S. Greenfield, Pfizer Inc., C; Pfizer Inc., R.
  • Footnotes
    Support  An unrestricted grant from Pfizer Inc., and Research to Prevent Blindness P30-EY14801
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 3497. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Sehi, D. S. Grewal, D. S. Greenfield; The Impact of Intraocular Pressure Reduction on Retinal Ganglion Cell Function Measured Using Pattern Electroretinogram in Eyes Receiving Latanoprost 0.005% versus Placebo. Invest. Ophthalmol. Vis. Sci. 2010;51(13):3497.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the impact of intraocular (IOP) reduction on retinal ganglion cell (RGC) function measured using pattern electroretinogram optimized for glaucoma (PERGLA) in eyes with glaucoma and ocular hypertension receiving latanoprost 0.005% versus placebo.

Methods: : This was a prospective, placebo-controlled, masked, crossover study. One randomly selected eye of each subject meeting eligibility criteria was enrolled. At each visit, subjects underwent 5 diurnal measurements between 8:00am and 4:00pm consisting of Goldmann IOP and PERGLA measurements. A baseline examination was performed following a four-week washout period, and repeat examination after randomly receiving latanoprost or placebo for four-weeks. Subjects were then crossed over to receive the alternative therapy for 4 weeks following a second washout period, and underwent repeat examination. Linear mixed-effect models for repeated measures, and stepwise regression analysis were performed.

Results: : Seventy-one patients (age 68.0±10.8 years, 50 males) were included. The mean IOP (mmHg) after latanoprost therapy (15.3±0.47) was significantly lower than baseline (18.9±4.2, p<0.001) or placebo (18.2±3.9, p<0.001). Mean PERGLA amplitude (µv) after latanoprost therapy (0.49±0.19) was similar to baseline (0.48±0.21, p=0.9) and placebo (0.49±0.21, p=0.9). The peak IOP in eyes receiving latanoprost or placebo was at 8:00-10:00am and the lowest IOP was at 2:00pm (p < 0.05). Change in PERGLA amplitude due to latanoprost was not correlated with age (r=0.08, p=0.5), ethnicity (rho= -0.02, p=0.6), gender (rho=0.24, p=0.05), baseline IOP (r=0.03, p=0.8), change in IOP (r=0.003, p=0.9), severity of VF loss (r= -0.06, p=0.6) or ocular diagnosis (rho=0.02, p=0.6).

Conclusions: : IOP reduction (mean 4-5mmHg) using latanoprost 0.005% as monotherapy is not associated with improvement in RGC function measured with PERGLA.

Keywords: ganglion cells • intraocular pressure • electrophysiology: clinical 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×